Hard on the heels of its Beantown-based rival, Boston Scientific, Abbott announced CE Marks for its Xience Prime and Xience V drug-eluting stents, clearing the way for their use in treating diabetes in the European Union.
The news follows BSX’s announcement of CE Marking for its Promus Element stent.
Chicago-based Abbott said EU regulators clearing its devices for use in treating coronary artery disease in difficult-to-treat diabetic patients, who tend to have smaller blood vessels and longer lesions.
Abbott won CE Mark approval for the Xience Prime in June and began marketing the device in Europe in August. The Xience V stent has been approved across the pond since 2006.
The company’s vascular segment posted sales of $666 million during the third quarter, up 4.7 percent excluding a hit from the weak dollar of 3.3 percent; U.S. vascular sales rose 5 percent during the period, to $395 million, and Q3 international vascular revenues rose to $271 million, a 4.3 percent increase.